Mesalamine

aspartic peptidase retroviral like 1 ; Homo sapiens







27 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 32786164 Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. 2020 Aug 12 2
2 32856298 Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. 2020 Aug 28 4
3 31810227 Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. 2019 Dec 2 1
4 27101467 Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. 2016 Apr 21 2
5 27648296 Usefulness of sulfasalazine for patients with refractory-ulcerative colits. 2016 3
6 25285021 Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. 2014 2
7 23076889 Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. 2012 Oct 17 2
8 19817724 Pilot study: the use of sulfasalazine for the treatment of acute pouchitis. 2010 Jan 15 1
9 16625536 Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. 2006 Apr 19 2
10 16625537 Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. 2006 Apr 19 2
11 16892148 [Current diagnostic status, clinical and pathologic manifestation for a Crohn's disease]. 2006 Aug 18 1
12 12917894 Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. 2003 2
13 12519547 Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. 2002 1
14 10796555 Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. 2000 1
15 10194945 [Clinical effect of various 5-ASA preparations in ulcerative colitis]. 1999 Feb 15 3
16 9893931 Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine. 1998 Dec 1
17 1351726 The effects of sulphasalazine and its metabolites on prostaglandin production by human mononuclear cells. 1992 Jun 9 2
18 1364279 The oxygen-centered radicals scavenging activity of sulfasalazine and its metabolites. A direct protection of the bowel. 1992 2
19 18475455 Mechanism of action of 5-arninosalicylic acid. 1992 2
20 1885075 Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. 1991 Aug 2
21 2902897 Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action? 1988 Oct 1
22 2890198 Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides. 1987 Sep 3
23 2875632 Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid. 1986 Jun 3
24 2877884 5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. 1986 4
25 2867770 Determination of the pK values of 5-aminosalicylic acid and N-acetylaminosalicylic acid and comparison of the pH dependent lipid-water partition coefficients of sulphasalazine and its metabolites. 1985 3
26 6121576 The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. 1982 Apr 2
27 36326 Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats. 1979 Aug 1